## Patrizia Casalini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11538864/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.9	1,356
2	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood, 2012, 120, 3007-3018.	1.4	350
3	microRNA-205 Regulates HER3 in Human Breast Cancer. Cancer Research, 2009, 69, 2195-2200.	0.9	334
4	FOXP3 Expression and Overall Survival in Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1746-1752.	1.6	271
5	Role of HER receptors family in development and differentiation. Journal of Cellular Physiology, 2004, 200, 343-350.	4.1	201
6	Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables. Journal of Clinical Oncology, 2001, 19, 329-335.	1.6	147
7	Oncosuppressive role of p53â€induced miRâ€205 in triple negative breast cancer. Molecular Oncology, 2012, 6, 458-472.	4.6	142
8	MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. European Journal of Cancer, 2008, 44, 2753-2759.	2.8	138
9	Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Letters, 2017, 384, 94-100.	7.2	131
10	Conversion to stem ell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. Molecular Oncology, 2016, 10, 253-271.	4.6	120
11	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. Cancer Discovery, 2014, 4, 110-129.	9.4	100
12	Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification. International Journal of Cancer, 1991, 47, 933-937.	5.1	99
13	HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. Journal of Clinical Oncology, 2003, 21, 458-462.	1.6	99
14	Breast cancer and microRNAs: therapeutic impact. Breast, 2011, 20, S63-S70.	2.2	87
15	FOXP3 expression in tumor cells and implications for cancer progression. Journal of Cellular Physiology, 2013, 228, 30-35.	4.1	87
16	miR-9 and miR-200 Regulate PDGFRÎ <sup>2</sup> -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 5562-5572.	0.9	74
17	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. Journal of Immunotherapy, 2007, 30, 684-693.	2.4	70
18	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. American Journal of Pathology, 2011, 179, 3000-3010.	3.8	62

PATRIZIA CASALINI

#	Article	IF	CITATIONS
19	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clinical Cancer Research, 2002, 8, 520-5.	7.0	58
20	Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene, 2004, 23, 2153-2160.	5.9	45
21	Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Research and Treatment, 1999, 55, 167-175.	2.5	44
22	Role of p53 in HER2-induced Proliferation or Apoptosis. Journal of Biological Chemistry, 2001, 276, 12449-12453.	3.4	44
23	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. PLoS ONE, 2013, 8, e56761.	2.5	41
24	PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Molecular Oncology, 2014, 8, 968-981.	4.6	37
25	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. Oncolmmunology, 2014, 3, e28989.	4.6	34
26	Expression of Concern: HER2 signaling enhances 5′UTRâ€mediated translation of câ€Myc mRNA. Journal of Cellular Physiology, 2004, 200, 82-88.	4.1	31
27	<b>Intratumor lactate levels reflect HER2 addiction status in HER2â€positive breast cancer</b> . Journal of Cellular Physiology, 2019, 234, 1768-1779.	4.1	31
28	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget, 2016, 7, 69649-69665.	1.8	29
29	Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: Analysis of cell binding and internalization. International Journal of Cancer, 1991, 48, 284-290.	5.1	20
30	Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. Clinical Cancer Research, 2008, 14, 25-31.	7.0	20
31	Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. , 1997, 72, 631-636.		19
32	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. Scientific Reports, 2019, 9, 14288.	3.3	17
33	Relationship between p53 and p27 expression following HER2 signaling. Breast, 2007, 16, 597-605.	2.2	16
34	The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. BMC Cancer, 2018, 18, 586.	2.6	16
35	Differential sensitivity of CD30+neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies. British Journal of Haematology, 1995, 90, 572-577.	2.5	14
36	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget, 2018, 9, 27920-27928.	1.8	14

PATRIZIA CASALINI

#	ARTICLE	IF	CITATIONS
37	Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells. Journal of Cellular Physiology, 2015, 230, 2661-2670.	4.1	13
38	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. European Journal of Cancer, 2006, 42, 1057-1061.	2.8	8
39	microRNA: New Players in Metastatic Process. , 2013, , .		2
40	Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools. , 2012, , 517-546.		2